换一批
换一批Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial.
作者：
主题词
抗风湿药(Antirheumatic Agents);关节炎, 类风湿(Arthritis, Rheumatoid);双盲法(Double-Blind Method);女(雌)性(Female);人类(Humans);白细胞介素1受体拮抗蛋白质(Interleukin 1 Receptor Antagonist Protein);长期医疗(Long-Term Care);男(雄)性(Male);中年人(Middle Aged);重组蛋白质类(Recombinant Proteins);安全(Safety);唾液糖蛋白类(Sialoglycoproteins)
DOI
10.1002/art.10578
PMID
12428223
发布时间
2022-03-17
- 浏览43
Arthritis and rheumatism
2838-46页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
